Home › Research › How common it is
Contribution of Modifiable Midlife and Late-Life Vascular Risk Factors to Incident Dementia
Smith JR, Pike JR, Gottesman RF, Knopman DS, Lutsey PL, Palta P, et al.. JAMA Neurology, 2025-07-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Importance Midlife vascular risk factors are associated with an elevated risk of dementia. Results A total of 7731 participants were included in analysis of risk factors measured at age 45 to 54 years (4494 female [58%]; 2207 Black [29%]; 5524 White [71%]), 12 274 contributed to analysis of risk factors measured at age 55 to 64 years (6698 female [55%]; 2886 Black [24%]; 9388 White [76%]), and 6787 contributed to analysis of risk factors measured at age 65 to 74 years (3764 female [56%], 1375 Black [20%]; 5412 White [80%]). Conclusions and relevance Results of this cohort study suggest that between 22% and 44% of incident dementia cases by 80 years in the ARIC study were attributed to midlife and late-life vascular risk factors.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 12,274 participants. In this cohort, between 22% and 44% of dementia cases by age 80 were attributed to vascular risk factors measured in midlife and late life. Reported effect size: 22-44% of dementia by age 80 attributable to hypertension, diabetes or smoking.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Smith, JR., Pike, JR., Gottesman, R. F., Knopman, D. S., Lutsey, P. L., Palta, P., et al. (2025). Contribution of Modifiable Midlife and Late-Life Vascular Risk Factors to Incident Dementia. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2025.1495
Vancouver
Smith JR, Pike JR, Gottesman RF, Knopman DS, Lutsey PL, Palta P, et al. Contribution of Modifiable Midlife and Late-Life Vascular Risk Factors to Incident Dementia. JAMA Neurology. 2025. doi:10.1001/jamaneurol.2025.1495. PMID: 40455489.
BibTeX
@article{smith2025-40455489,
author = {Smith, JR. and Pike, JR. and Gottesman, R. F. and Knopman, D. S. and Lutsey, P. L. and Palta, P. and others},
title = {{Contribution of Modifiable Midlife and Late-Life Vascular Risk Factors to Incident Dementia}},
journal = {JAMA Neurology},
year = {2025},
doi = {10.1001/jamaneurol.2025.1495},
pmid = {40455489},
url = {https://doi.org/10.1001/jamaneurol.2025.1495}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Importance Midlife vascular risk factors are associated with an elevated risk of dementia.
- Results A total of 7731 participants were included in analysis of risk factors measured at age 45 to 54 years (4494 female [58%]; 2207 Black [29%]; 5524 White [71%]), 12 274 contributed to analysis of risk factors measured at age 55 to 64 years (6698 female [55%]; 2886 Black [24%]; 9388 White [76%]), and 6787 contributed to analysis of risk factors measured at age 65 to 74 years (3764 female [56%], 1375 Black [20%]; 5412 White [80%]).
- Conclusions and relevance Results of this cohort study suggest that between 22% and 44% of incident dementia cases by 80 years in the ARIC study were attributed to midlife and late-life vascular risk factors.
Why it matters
In this cohort, between 22% and 44% of dementia cases by age 80 were attributed to vascular risk factors measured in midlife and late life. This suggests that managing vascular risk factors could play a role in reducing dementia cases, though the study shows association rather than proven cause and effect.
New to this subject? Start with our plain-English guide: Alzheimer's in numbers →
Study details
- Study designcohort
- Participants12,274
- Effect size22-44% of dementia by age 80 attributable to hypertension, diabetes or smoking
- Evidence strengthModerate
Limitations
Assumes causal relationships; four US communities; risk factors defined by single-visit measurements.
How this study scored 69/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 68 of the 98 points we could judge it on, which is 69 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA Neurology) |
| Journal's citation record | 2 / 4 | JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 4 / 4 | 12,274 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 47 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 15.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 5 / 6 | Cited 29.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 5 other studies in this library |
| Still being cited | 2 / 4 | Cited 47 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Jennifer A. Deal: h-index 45 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Johns Hopkins University: institution h-index 2,306 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40455489) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 68 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 68 of the 98 points we could judge it on is 69 out of 100. |
| Total | 69 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamaneurol.2025.1495
- PubMed: 40455489
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 24.
Later studies that cite this one
5 studies in the alzhub library list this one in their references.
Related studies in How common it is from nearby years
Also tagged “biobank”
1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.